RESUMEN
Mucormycosis is the third most frequent invasive mycosis, following candidiasis and aspergillosis. It is frequently neglected due to its rare occurrence; but recently attend the status of notifiable disease due to its higher incidence in both developed and developing nations. India has received global notice since its estimated instances were greater than the global estimated figures. Mucormycosis has several clinical manifestations, including rhino-orbital-cerebral (ROCM), pulmonary, gastrointestinal, cutaneous, renal, and diffuse Mucormycosis. ROCM is the most frequent clinical manifestation in India, although pulmonary mucormycosis is prevalent worldwide. This review also discusses host defenses, pre disposing risk factors and fungal virulence factors that impair host's ability to prevent fungus invasion and disease establishment. The diagnosis of the disease depends on clinical interventions, histological or microbiological procedures along with molecular methods to obtain timely results. But there are still unmet challenges for rapid diagnosis of the disease. Treatment of the disease is achieved by multimodal approaches such as reversal of underlying predisposing factors, rapid administration of antifungals in optimal doses and surgical procedures to remove infected tissues. Liposomal Amphotericin B, Posaconazole and Isavuconazoles are preferred as the first line of treatment procedures. clinical trials. Different studies have improved the existing drug and under clinical trials while several studies predicted the new potential targets as CotH and Ftr1 as shown in infection and in vitro models. Therefore, current scenario demands a multidisciplinary approach is needed to investigate the prevalence, pathogenesis which is highly important for the advancement of rapid diagnosis and effective treatment.
Asunto(s)
Antifúngicos , Mucormicosis , Enfermedades Raras , Humanos , Mucormicosis/epidemiología , Mucormicosis/microbiología , Mucormicosis/tratamiento farmacológico , Mucormicosis/diagnóstico , Antifúngicos/uso terapéutico , Enfermedades Raras/microbiología , India/epidemiología , Factores de RiesgoRESUMEN
Dermatophytic pseudomycetoma is a rare invasive infection, involving both immunocompetent and immunocompromised individuals. Since the discovery of inherited immune disorders such as the impairment of CARD9 gene, extended dermatophyte infections are mostly ascribed to any of these host factors. This study is to present and explore the potential causes in a fatal dermatophytic pseudomycetoma patient. We present a chronic and deep pseudomycetoma caused by the common dermatophyte Microsporum canis which ultimately led to the death of the patient. Mycological examination, genetic studies and host immune responses against fungi were performed to explore the potential factors. The patient had decreased lymphocyte counts with significantly reduced CD4+ T cells, although all currently known genetic parameters proved to be normal. Through functional studies, we demonstrated that peripheral blood mononuclear cells from the patient showed severe impairment of adaptive cytokine production upon fungus-specific stimulation, whereas innate immune responses were partially defective. This is, to our knowledge, the first report of fatal dermatophytic pseudomycetoma in a patient with non-HIV CD4 lymphocytopenia, which highlights the importance of screening for immune deficiencies in patients with deep dermatophytosis.
Asunto(s)
Dermatomicosis , Microsporum , Enfermedades Raras , Humanos , Dermatomicosis/genética , Dermatomicosis/inmunología , Dermatomicosis/microbiología , Micetoma/genética , Micetoma/inmunología , Micetoma/microbiología , Femenino , Persona de Mediana Edad , Microsporum/aislamiento & purificación , Resultado Fatal , Caspasa 9/genética , Receptores de Interleucina-7/genética , Mutación , Enfermedades Raras/genética , Enfermedades Raras/inmunología , Enfermedades Raras/microbiología , Recuento de Linfocito CD4 , Inmunidad InnataRESUMEN
Invasive infections with emerging yeasts such as Geotrichum, Saprochaete/Magnusiomyces, Trichosporon, and other species are associated with high morbidity and mortality rates. Due to the rarity and heterogeneity of these yeasts, medical mycology has lacked guidance in critical areas affecting patient management. Now, physicians and life scientists from multiple disciplines and all world regions have united their expertise to create the "Global guideline for the diagnosis and management of rare yeast infections: an initiative of the European Confederation of Medical Mycology in cooperation with the International Society for Human and Animal Mycology and the American Society for Microbiology." Recommendations are stratified for high- and low-resource settings and are therefore applicable worldwide. The advantages and disadvantages of various diagnostic methods and treatment options are outlined. This guideline reflects the current best-practice management for invasive rare yeast infections in a range of settings, with the intent of establishing a global standard of care for laboratorians and clinicians alike.
Asunto(s)
Micosis/diagnóstico , Enfermedades Raras/diagnóstico , Enfermedades Raras/microbiología , Antifúngicos/uso terapéutico , Humanos , Micología/métodos , Micosis/tratamiento farmacológico , Micosis/patologíaRESUMEN
BACKGROUND: Conidiobolomycosis is a rare tropical rhinofacial fungal infection which has not been well characterised. The available evidence in its management is sparse due to lack of clinical studies and the limited data on antifungal susceptibility patterns. OBJECTIVE: To analyse the clinical manifestations, antifungal treatment and outcomes of patients with conidiobolomycosis and to determine antifungal susceptibility profiles of the isolates. PATIENTS/METHODS: Retrospective analysis of data of all patients with a diagnosis of conidiobolomycosis confirmed by histopathology and culture at a tertiary care hospital from 2012 to 2019 was done. RESULTS: There were 22 patients, 21 males and one female, with a mean age of 37.1 years. Most common presenting symptom was nasal obstruction, found in 20 (90.90%) patients. Patients who presented within 12 months had a better cure rate (85%) compared to those who presented late (67%). Among the 19 patients who had a follow-up, good outcome was seen in 15 of the 17 (88.24%) patients who were on itraconazole or potassium iodide containing regimen. Of the six patients who received additional trimethoprim-sulphamethoxazole (co-trimoxazole), 67% showed good outcome with two patients showing complete cure and two patients still on treatment with significant improvement. High minimum inhibitory concentration (MIC) values were noted for azoles and amphotericin B, whereas co-trimoxazole showed lowest MIC ranges. CONCLUSION: Itraconazole and potassium iodide are reasonable first-line options for the treatment of conidiobolomycosis. Good clinical response to KI and comparatively lower MIC of co-trimoxazole are promising. Further studies are required for developing clinical breakpoints that can predict therapeutic outcomes.
Asunto(s)
Antifúngicos/uso terapéutico , Conidiobolus/efectos de los fármacos , Enfermedades Raras/microbiología , Cigomicosis/tratamiento farmacológico , Cigomicosis/microbiología , Adulto , Manejo de la Enfermedad , Cara/microbiología , Cara/patología , Femenino , Humanos , Masculino , Pruebas de Sensibilidad Microbiana , Persona de Mediana Edad , Enfermedades Nasales/tratamiento farmacológico , Enfermedades Nasales/microbiología , Enfermedades Raras/tratamiento farmacológico , Estudios Retrospectivos , Centros de Atención Terciaria/estadística & datos numéricos , Adulto JovenRESUMEN
This is a rare case report of two filamentous fungi in a patient with contact lens related keratitis. An early corneal scrape may be useful in detecting multiple causative pathogens and aiding management. The main learning point is to consider fungal infections in patients with atypical ulcer appearances, as prompt diagnosis may reduce the morbidity burden.
Asunto(s)
Lentes de Contacto/microbiología , Infecciones Fúngicas del Ojo/tratamiento farmacológico , Infecciones Fúngicas del Ojo/microbiología , Hongos/aislamiento & purificación , Queratitis/tratamiento farmacológico , Queratitis/microbiología , Enfermedades Raras/tratamiento farmacológico , Antifúngicos/uso terapéutico , Infecciones Fúngicas del Ojo/diagnóstico , Femenino , Fusarium/aislamiento & purificación , Humanos , Hypocreales/aislamiento & purificación , Queratitis/diagnóstico , Persona de Mediana Edad , Enfermedades Raras/diagnóstico , Enfermedades Raras/microbiología , Resultado del Tratamiento , Reino Unido , Voriconazol/uso terapéuticoAsunto(s)
Trastornos de la Motilidad Ciliar/fisiopatología , Enfermedades Raras/fisiopatología , Adulto , Factores de Edad , Antibacterianos/uso terapéutico , Bronquiectasia/etiología , Niño , Trastornos de la Motilidad Ciliar/diagnóstico por imagen , Trastornos de la Motilidad Ciliar/microbiología , Fibrosis Quística/microbiología , Fibrosis Quística/fisiopatología , Progresión de la Enfermedad , Femenino , Volumen Espiratorio Forzado , Humanos , Síndrome de Kartagener/diagnóstico por imagen , Síndrome de Kartagener/microbiología , Síndrome de Kartagener/fisiopatología , Pulmón/diagnóstico por imagen , Masculino , Fenotipo , Pronóstico , Enfermedades Raras/diagnóstico por imagen , Enfermedades Raras/microbiología , Análisis de Regresión , Infecciones del Sistema Respiratorio/tratamiento farmacológico , Infecciones del Sistema Respiratorio/prevención & control , Estudios Retrospectivos , Tomografía Computarizada por Rayos X , Capacidad VitalAsunto(s)
Infecciones por Helicobacter/diagnóstico por imagen , Helicobacter heilmannii , Úlcera Péptica/diagnóstico por imagen , Enfermedades Raras/diagnóstico por imagen , Anciano de 80 o más Años , Endoscopía Gastrointestinal , Femenino , Infecciones por Helicobacter/microbiología , Helicobacter heilmannii/aislamiento & purificación , Humanos , Úlcera Péptica/microbiología , Enfermedades Raras/microbiologíaRESUMEN
BACKGROUND: Kosakonia cowanii, formerly known as Enterobacter cowanii, is a Gram-negative bacillus belonging to the order Enterobacterales. The species is usually recognized as a plant pathogen and has only anecdotally been encountered as a human pathogen. Here we describe the rare case of a K. cowanii infection presenting as an acute cholecystitis and provide a review of available literature. Evident difficulties in species identification by biochemical profiling suggests that potentially, K. cowanii might represent an underestimated human pathogen. CASE PRESENTATION: A 61-year old immunocompromised man presented to the hospital with fever and pain in the upper right abdomen. Sonography revealed an inflamed gall bladder and several gall stones. A cholecystectomy proved diagnosis of an acute cholecystitis with a partial necrosis of the gall bladder. Surgical specimen grew pure cultures of Gram-negative rods unambiguously identified as K. cowanii by MALDI-TOF, 16S-rRNA analysis and whole genome sequencing. CONCLUSIONS: Reporting cases of Kosakonia species can shed light on the prevalence and clinical importance of this rare cause of human infection. Our case is the first to describe an infection without prior traumatic inoculation of the pathogen from its usual habitat, a plant, to the patient. This raises the question of the route of infections as well as the pathogen's ability to colonize the human gut.
Asunto(s)
Colecistitis Aguda/diagnóstico , Colecistitis Aguda/microbiología , Infecciones por Enterobacteriaceae/diagnóstico , Enterobacteriaceae/genética , Enfermedades Raras/diagnóstico , Enfermedades Raras/microbiología , Colecistectomía , Infecciones por Enterobacteriaceae/microbiología , Vesícula Biliar/patología , Cálculos Biliares/cirugía , Humanos , Huésped Inmunocomprometido , Masculino , Persona de Mediana Edad , Necrosis , ARN Bacteriano/genética , ARN Ribosómico 16S/genética , Resultado del Tratamiento , Secuenciación Completa del GenomaRESUMEN
BACKGROUND: Fungaemia due to rare yeasts has been recognised as an emerging, clinically relevant, but less investigated condition. Intrinsic resistance or reduced susceptibility of these species to echinocandins or fluconazole remains as a challenge in empirical treatment. OBJECTIVES: To describe the clinical characteristics, administered antifungal agents, outcomes of patients with rare yeasts other than Candida (RY-OTC) fungaemia and determine the antifungal susceptibility profiles of the isolates. PATIENTS AND METHODS: RY-OTC fungaemia between January-2001 and December-2018 were retrospectively evaluated. Antifungal susceptibility tests were performed according to CLSI M27-A3. RESULTS: We identified 19 patients with fungaemia due to 20 RY-OTC (8 Trichosporon asahii, 4 Cryptococcus neoformans, 4 Saprochaete capitata, 3 Rhodotorula mucilaginosa, 1 Trichosporon mucoides) with an incidence of 2.2% among 859 fungaemia episodes. Haematological malignancy was the most common (42%) underlying disorder. In 6 patients, RY-OTC fungaemia developed as breakthrough infection while receiving echinocandins, amphotericin B or fluconazole. Amphotericin B, fluconazole or voriconazole were the drugs of choice for the initial treatment of breakthrough fungaemia. Among patients without previous exposure to antifungals, the most common empirical treatment was an echinocandin (50%), followed by fluconazole (42%) and amphotericin B (8%). Overall mortality was 47%. Worse outcome was most common among patients receiving echinocandins (83% vs 25%, P < .05). Voriconazole and posaconazole showed the highest in vitro activity against all the isolates tested. Amphotericin B MICs were relatively higher and the degree of activity of fluconazole and itraconazole was variable. CONCLUSIONS: Early recognition of RY-OTC and knowledge about their susceptibility patterns remain crucial in initial treatment pending susceptibility data of isolates.
Asunto(s)
Antifúngicos/uso terapéutico , Fungemia/microbiología , Enfermedades Raras/microbiología , Adulto , Anciano , Farmacorresistencia Fúngica , Femenino , Fungemia/tratamiento farmacológico , Fungemia/mortalidad , Hongos/clasificación , Hongos/efectos de los fármacos , Hongos/aislamiento & purificación , Humanos , Masculino , Pruebas de Sensibilidad Microbiana , Persona de Mediana Edad , Estudios Retrospectivos , Atención Terciaria de Salud , Turquía , UniversidadesRESUMEN
BACKGROUND: Localized `and disseminated Nocardia farcinica infection is frequently reported in immunocompromised patients. However, orbital nocardiosis is rare, and, to our knowledge, traumatic orbital nocardiosis that affects the brain has never been described. Here, we report a case of traumatic orbital and intracranial N. farcinica infection in an immunocompetent patient. CASE PRESENTATION: A 35-year-old man, who was immunocompetent, to the best of our knowledge and as per the absence of immunodeficiency symptoms, with orbital trauma caused by the penetration of a rotten bamboo branch developed lesions in the orbit and brain. Subsequently, he underwent debridement and received broad-spectrum antibiotic therapy, but orbital infection occurred, with drainage of pus through the sinus tract. The patient then underwent endoscope-assisted local debridement. Bacterial culture of the sinusal pus was positive for N. farcinica, and a combined intracranial infection had developed. The disease was treated effectively by trimethoprim-sulfamethoxazole and ceftriaxone sodium therapy. The patient remained infection free and without complications at the 14-month follow-up. CONCLUSIONS: Traumatic orbital and intracranial infection caused by N. farcinica is a rare infectious disease, and atypical presentations easily lead to misdiagnosis. When a patient presents with an atypical orbital infection that is unresponsive to empirical broad-spectrum antibiotics, along with suspicious neurologic symptoms, Nocardia infection should be considered. Identification by bacterial culture is the gold standard. Complete local debridement and appropriate antibiotic treatment are keys to the treatment of the disease.
Asunto(s)
Lesiones Oculares Penetrantes/microbiología , Nocardiosis/diagnóstico , Nocardiosis/microbiología , Nocardia/aislamiento & purificación , Órbita/lesiones , Adulto , Antibacterianos/uso terapéutico , Ceftriaxona/uso terapéutico , Desbridamiento , Drenaje , Estudios de Seguimiento , Humanos , Huésped Inmunocomprometido , Masculino , Nocardiosis/tratamiento farmacológico , Nocardiosis/cirugía , Enfermedades Raras/diagnóstico , Enfermedades Raras/tratamiento farmacológico , Enfermedades Raras/microbiología , Enfermedades Raras/cirugía , Sasa/microbiología , Resultado del Tratamiento , Combinación Trimetoprim y Sulfametoxazol/uso terapéuticoRESUMEN
BACKGROUND: Osteomyelitis of the pubic symphysis is a rare cause of pelvic pain after delivery, mainly caused by Staphylococcus aureus and Pseudomonas aeruginosa. The clinical context is the same as the more common diastasis of the pubic bone, but the presence of intense local pain in association with fever should prompt further clinical work-up based on blood chemistry, microbiology and diagnostic imaging. We report the first case of methicillin-resistant Staphylococcus aureus osteomyelitis of the pubic symphysis occuring after the delivery. CASE PRESENTATION: A 39-year-old woman developed pain over the pubic bone 12 h after the delivery. After 72 h fever rose and laboratory examination showed elevation of C-reactive protein and procalcitonin levels. Pelvic x-rays and magnetic resonance showed pubic diastasis, joint effusion, tiny irregularities of articular surfaces and, severe bone edema. The patient was started on broad spectrum intravenous (IV) antibiotics (piperacillin-tazobactam) and then replaced to IV vancomycin and oral levofloxacin based on antibiogram result. She was then discharged with oral antibiotic therapy and fully recovered. CONCLUSIONS: Due to the rarity of this disease, we compared our experience with the other cases of osteomyelitis of pubic symphysis occurring in peri-postpartum reported in the literature. The course of osteomyelitis was favourable in all patients, and only in one case an additional orthopedic procedure for symphysis fixation was necessary. Knowledge of this rare condition is important to enable prompt diagnosis and treatment.
Asunto(s)
Parto Obstétrico , Staphylococcus aureus Resistente a Meticilina/aislamiento & purificación , Osteomielitis/microbiología , Sínfisis Pubiana/patología , Infecciones Estafilocócicas/microbiología , Adulto , Antibacterianos/uso terapéutico , Femenino , Fiebre/tratamiento farmacológico , Humanos , Levofloxacino/uso terapéutico , Imagen por Resonancia Magnética , Pruebas de Sensibilidad Microbiana , Osteomielitis/diagnóstico por imagen , Osteomielitis/tratamiento farmacológico , Periodo Posparto , Embarazo , Pseudomonas aeruginosa/aislamiento & purificación , Sínfisis Pubiana/diagnóstico por imagen , Enfermedades Raras/diagnóstico por imagen , Enfermedades Raras/tratamiento farmacológico , Enfermedades Raras/microbiología , Infecciones Estafilocócicas/tratamiento farmacológico , Resultado del Tratamiento , Vancomicina/uso terapéuticoRESUMEN
BACKGROUND: Tularaemia is a zoonotic disease caused by inoculation with the Gram-negative coccobacillus Francisella tularensis. It was first described in the United States in 1911 and is a rare disease with an annual reported incidence in France between 2002 and 2012 of 0.07 cases per 100,000 habitants. Reporting of the disease in humans has been mandatory in France since 2003. PATIENTS AND METHODS: Herein we report a case of tularaemia following a tick bite in a patient in the north of France. DISCUSSION: Tularaemia is a rare form of zoonosis that should be sought in the event of unexplained adenitis. Clinical presentations vary, and in certain cases only dermatological signs are manifest. Diagnosis is confirmed by bacterial serology. Rapid initiation of suitable antibiotics produces a favourable and benign outcome in most cases. However, the offending organism, which is potentially lethal, is classed as a potential bioterrorism agent.
Asunto(s)
Enfermedades Raras/microbiología , Mordeduras de Garrapatas/complicaciones , Tularemia/transmisión , Francia , Francisella tularensis/inmunología , Ingle , Humanos , Linfadenitis/microbiología , Masculino , Enfermedades Raras/tratamiento farmacológico , Tularemia/tratamiento farmacológicoRESUMEN
WHAT IS KNOWN AND OBJECTIVE: Lemierre's syndrome is often misdiagnosed as a common cold or viral infection. Fusobacterium necrophorum is the most common causative organism. The recommended treatment regimen is 6 weeks of a beta-lactam antibiotic along with metronidazole. CASE DESCRIPTION: We present two cases of Lemierre's syndrome with internal jugular vein thrombophlebitis and positive blood cultures for F. necrophorum. The first case was successfully treated with 6 weeks of a beta-lactam antibiotic and 4 weeks of metronidazole, while the second case was successfully treated with 4 weeks of a beta-lactam antibiotic and 2 weeks of metronidazole. WHAT IS NEW AND CONCLUSION: Two cases of Lemierre's syndrome were treated successfully with only 2-4 weeks of metronidazole therapy. Shorter duration of metronidazole therapy should be explored in future studies.
Asunto(s)
Antibacterianos/administración & dosificación , Infecciones por Fusobacterium/diagnóstico , Síndrome de Lemierre/diagnóstico , Tromboflebitis/etiología , Adulto , Femenino , Infecciones por Fusobacterium/tratamiento farmacológico , Infecciones por Fusobacterium/microbiología , Fusobacterium necrophorum/aislamiento & purificación , Humanos , Venas Yugulares/patología , Síndrome de Lemierre/tratamiento farmacológico , Síndrome de Lemierre/microbiología , Masculino , Metronidazol/administración & dosificación , Enfermedades Raras/diagnóstico , Enfermedades Raras/tratamiento farmacológico , Enfermedades Raras/microbiología , Tromboflebitis/microbiología , beta-Lactamas/administración & dosificaciónAsunto(s)
Adenocarcinoma Mucinoso/microbiología , Adenocarcinoma Mucinoso/fisiopatología , Adenocarcinoma Papilar/microbiología , Adenocarcinoma Papilar/fisiopatología , Antibacterianos/uso terapéutico , Carcinoma Ductal Pancreático/microbiología , Carcinoma Ductal Pancreático/fisiopatología , Infecciones/tratamiento farmacológico , Adenocarcinoma Mucinoso/complicaciones , Adenocarcinoma Mucinoso/diagnóstico por imagen , Adenocarcinoma Papilar/complicaciones , Adenocarcinoma Papilar/diagnóstico por imagen , Anciano , Carcinoma Ductal Pancreático/complicaciones , Carcinoma Ductal Pancreático/diagnóstico por imagen , Femenino , Humanos , Enfermedades Raras/microbiologíaAsunto(s)
Costo de Enfermedad , Hongos/patogenicidad , Micosis/epidemiología , Enfermedades Raras/microbiología , Fibrosis Quística/complicaciones , Fibrosis Quística/epidemiología , Hongos/aislamiento & purificación , Humanos , Infecciones Fúngicas Invasoras/diagnóstico , Infecciones Fúngicas Invasoras/epidemiología , Infecciones Fúngicas Invasoras/microbiología , Micosis/diagnóstico , Micosis/microbiología , Enfermedades Raras/diagnóstico , Enfermedades Raras/epidemiología , Reino Unido/epidemiologíaRESUMEN
Actinomycosis is a rare and heterogeneous infection involving Gram-positive anaerobic bacteria, which are commensals in the oral cavity and digestive tract. Only four cases of actinomycosis in renal transplant recipients have been reported to date. We performed a retrospective study in French renal transplantation centers to collect data about actinomycosis, patients, and transplantation. Seven cases were reported between 2000 and 2017; mean age was 55.7 years, and prevalence of actinomycosis was 0.02%. Median time between transplantation and infection was 104 months (4-204 months). Locations of actinomycosis were cervicofacial (n = 2), pulmonary (n = 2), abdominopelvic (n = 2), or cutaneous (n = 1). Two patients (28.5%) had acute kidney injury. Diagnosis was made possible by microbiology (71%) or histopathology (filaments and sulfur granules) (14%) of the infection site. The suspected gate of entry for the infection was dental (57%), abdominal (28.5%) or through the sinuses (14%). All patients were treated with amoxicillin for 30-200 days (median duration of 115 days), and clavulanic acid was added for 28.5% of cases. Three patients (43%) required surgery. All patients, except one, recovered completely after a few months. Actinomycosis is a rare, slow, progressive disease in French renal transplant recipients. The location and clinical features of this infection are miscellaneous. Global and renal outcomes do not seem to be affected by actinomycosis.
Asunto(s)
Actinomyces/aislamiento & purificación , Actinomicosis/epidemiología , Antibacterianos/uso terapéutico , Fallo Renal Crónico/cirugía , Trasplante de Riñón/efectos adversos , Enfermedades Raras/epidemiología , Actinomicosis/diagnóstico , Actinomicosis/tratamiento farmacológico , Actinomicosis/microbiología , Adulto , Anciano , Amoxicilina/uso terapéutico , Ácido Clavulánico/uso terapéutico , Quimioterapia Combinada/métodos , Femenino , Francia/epidemiología , Rechazo de Injerto/prevención & control , Humanos , Terapia de Inmunosupresión/efectos adversos , Masculino , Persona de Mediana Edad , Prevalencia , Enfermedades Raras/diagnóstico , Enfermedades Raras/tratamiento farmacológico , Enfermedades Raras/microbiología , Estudios Retrospectivos , Resultado del TratamientoRESUMEN
Invasive fungal disease (IFD) confers a substantial risk for morbidity and mortality to immunocompromised patients. Invasive aspergillosis (IA) is the most common IFD caused by moulds but the prevalence of other rare mould diseases, such as mucormycosis, hyalohyphomycosis and phaeohyphomycosis, may be increasing. Treatments are available for IA, but evidence to support efficacy and safety of antifungal agents for rare IFDs, or for IFDs in special patient populations, is limited or lacking. The VITAL trial was conducted to assess the efficacy and safety of isavuconazole for the treatment of patients with IA and renal impairment, or with IFDs caused by rare moulds, yeasts or dimorphic fungi. These patients stand to benefit most from a new treatment option but are unlikely to be included in a randomised, controlled trial. In this article, we review the challenges faced in the design and conduct of the VITAL trial. We also review the findings of VITAL, which included evidence of the efficacy and safety of isavuconazole. Finally, we consider the importance of trials such as VITAL to inform therapeutic decision making for clinicians faced with the challenge of treating patients with rare IFDs and as one paradigm of how to determine efficacy and safety of new drugs for rare and resistant infections without a suitable comparator.
Asunto(s)
Antifúngicos/uso terapéutico , Infecciones Fúngicas Invasoras/tratamiento farmacológico , Aspergilosis Pulmonar Invasiva/tratamiento farmacológico , Micosis/tratamiento farmacológico , Nitrilos/uso terapéutico , Piridinas/uso terapéutico , Ensayos Clínicos Controlados Aleatorios como Asunto , Insuficiencia Renal/microbiología , Triazoles/uso terapéutico , Adulto , Antifúngicos/administración & dosificación , Antifúngicos/efectos adversos , Hongos/efectos de los fármacos , Humanos , Huésped Inmunocomprometido , Persona de Mediana Edad , Mucormicosis/tratamiento farmacológico , Micosis/microbiología , Nitrilos/administración & dosificación , Nitrilos/efectos adversos , Piridinas/administración & dosificación , Piridinas/efectos adversos , Enfermedades Raras/tratamiento farmacológico , Enfermedades Raras/microbiología , Insuficiencia Renal/complicaciones , Triazoles/administración & dosificación , Triazoles/efectos adversosRESUMEN
Candida fungus ball is a rare presentation of urinary tract infections among adult patients and is associated with considerable morbidity. Because clinical signs are not specific, diagnosis is often delayed. Furthermore, treatment is occasionally difficult, and the approach to such cases varies widely among different centers. In this report, we describe a patient with retroperitoneal fibrosis who developed a renal fungus ball. Management of this challenging case is discussed, and review of the literature is presented.
Asunto(s)
Candida albicans/aislamiento & purificación , Candidiasis/microbiología , Riñón/microbiología , Enfermedades Raras/microbiología , Fibrosis Retroperitoneal/complicaciones , Infecciones Urinarias/microbiología , Adulto , Antifúngicos/uso terapéutico , Candida albicans/efectos de los fármacos , Candidiasis/complicaciones , Candidiasis/tratamiento farmacológico , Manejo de la Enfermedad , Fluconazol/uso terapéutico , Humanos , Riñón/patología , Masculino , Enfermedades Raras/complicaciones , Enfermedades Raras/tratamiento farmacológico , Fibrosis Retroperitoneal/tratamiento farmacológico , Fibrosis Retroperitoneal/microbiología , Resultado del Tratamiento , Infecciones Urinarias/complicaciones , Infecciones Urinarias/tratamiento farmacológicoRESUMEN
A 35-year-old woman with severe cystic fibrosis was admitted for sudden loss of strength in both legs, revealing a myelitis. The medullary lesion biopsy revealed phaeohyphomycosis caused by Cladophialophora species. Myelitis caused by Cladophialophora bantiana is a rare disease associated with high mortality.